淀粉样轻链淀粉样变性病的医疗资源利用及成本：一项利用美国理赔数据的真实世界研究
Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data.
作者信息
Quock Tiffany P, Yan Tingjian, Chang Eunice, Guthrie Spencer, Broder Michael S
机构信息
Prothena Biosciences Inc, 331 Oyster Point Boulevard; South San Francisco, CA 94080, USA.
Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr. Ste. 404, Beverly Hills, CA 90212, USA.
出版信息
J Comp Eff Res. 2018 Jun;7(6):549-559. doi: 10.2217/cer-2017-0100. Epub 2018 Feb 2.
AIM
To estimate healthcare utilization and costs in amyloid light-chain (AL) amyloidosis.
PATIENTS & METHODS: AL amyloidosis patients were identified in 2007-2015 claims databases if they had ≥1 inpatient/≥2 outpatient claims consistent with AL amyloidosis and received ≥1 AL-specific treatment. Descriptive statistics were reported.
RESULTS
50.1% (n = 3670) were admitted ≥1 time during the year, 11.3% (n = 827) ≥3 times. From 2007 to 2015, bortezomib use increased from 4.6 to 25.3%; melphalan use decreased from 18.9 to 2.0%; costs increased from 92,866 to $114,030. Among incident patients with at least 2 years of follow-up, healthcare utilization and costs decreased from first to second year post-diagnosis.
CONCLUSION
AL chemotherapy-based prescribing practices changed. Total annual healthcare costs increased over time among AL amyloidosis patients.
目的
评估轻链（AL）淀粉样变性患者的医疗服务利用情况及费用。
患者与方法
2007年至2015年的理赔数据库中识别出AL淀粉样变性患者，条件为他们有≥1次住院/≥2次门诊理赔记录与AL淀粉样变性相符且接受了≥1次AL特异性治疗。报告描述性统计数据。
结果
50.1%（n = 3670）患者在一年内住院≥1次，11.3%（n = 827）患者住院≥3次。从2007年到2015年，硼替佐米的使用从4.6%增至25.3%；美法仑的使用从18.9%降至2.0%；费用从92,866美元增至114,030美元。在至少随访2年的初发患者中，医疗服务利用情况及费用在诊断后的第一年到第二年有所下降。
结论
基于AL化疗的处方实践发生了变化。AL淀粉样变性患者的年度医疗总费用随时间增加。
Zotero 插件